New treatment modalities - The urologist's view

Anticancer Research

Volumn 19, Issue 2 C, 1999, Pages 1605-1609

  Strohmaier, Walter Ludwig ^a  

^a Landkrankenhaus Coburg ^*  (Germany)

Author keywords

Angiogenesis; Gene therapy; Immunotherapy; Nephrectomy; Renal cell cancer

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; FLUOROURACIL; HEMOGLOBIN; INTERLEUKIN 2;

BONE METASTASIS; CANCER IMMUNOTHERAPY; CANCER RISK; CANCER SURVIVAL; CONFERENCE PAPER; GRANULOCYTE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CARCINOMA; NEPHRECTOMY; NEUTROPHIL; PRIORITY JOURNAL; RESEARCH; SUBCUTANEOUS DRUG ADMINISTRATION; TOXICITY;

ANTIBODIES, MONOCLONAL; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; FLUOROURACIL; GENE THERAPY; HUMANS; IMMUNOTHERAPY; INTERFERON ALFA-2A; INTERLEUKIN-2; KIDNEY NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0033049824     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (57)

1. Arbeitsgemeinschaft Bevolkerungsbezogener Krebsregister: Krebs-Inzidenz und -Mortalitat in Deutschland: Prozentuale Anteile für das Jahr 1995. Fokus Onkologie 1: 58, 1998.
2. Wunderlich H, Schwnann S, Janitzky V, Moravek P, Podhola M, Kosmehl H, Schubert J: Increase of renal cell carcinoma incidence in Central Europe. Eur Urol 33: 538-541, 1998.
3. Bono AV, Lovisolo 3AJ: Renal cell carcinoma - diagnosis and treatment: state of the art. Eur Urol 31 suppl 1: 7-55, 1997.
4. Figlin RA, Pierce WC, Kaboo R, Lea Tso C, Moldawer N, Gitlitz B, DeKerDion J, Belldegruen A: Tretament of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytolcine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor. J Urol 158: 740-745, 1997.
5. Patel NP, Lavengood RW: Renal cell carcinoma: nahllal history and results of treatment. I Urol 119: 722-726, 1978.
6. Yagoda A, Abi-Racbed B, Petrylak D: Chemotherapy for advanced renal-cell carcinoma 1983-1993. Sem Oncol 22: 42-60, 1995.
7. Dillman RO, Church C, Oldbam RK, Wets WH, Schwartzberg L, Birch R Inpatient continuous infusion interleukin 2 in 788 patients with cancer. Cancer 71: 2358-2370, 1993.
8. Whitehead RP, Blumenstein B, Flamgan RC, Weiss GR, Culkin DJ, Bearman SJI, Dakil S, Crawford ED: Phase II trial of recombinant human interleukin-4 (rhulLA) in patients with disseminated rellal cell adenocarcinoma A Southwest Oncology Group (SWOG) study. Proc ASCO 15: A259, 1996.
9. Stoutbard IML, Goey H, de Vries EGE, de Mulder H, Groenewegen A, Pronk L, Stoter G, Sauerwein HP, Bakker PJM, Veenhof CHN: Recombinant human interleukin 6 in metastatic renal cell cancer: a phase II trial. Br J Cancer 73: 789-793, 1996.
10. Wos E, Olencki T, Tuason L, Budd GI, Peereboom D, Sandstorm K, McLain D, Finke J, Bukowski RM: Phase II trial of subcutaneously admnisteled granulocyte-macrophage colony-stimulating factor in patients with metastatic renal cell carcinoma. Cancer 77: 1149-1153, 1996.
11. Strohmaier WL, Kalchthaler M, Kleinknecht S, Bichler KH: Interleukin II (IL II) und Interferon Gamma (IFG)- Therapie beim metastasierten Nierenzellkarzinom (NZK). Z Urologie Postes 1: 18-19, 1993.
12. Wigginton IM, Komscblies KL, Back TC, Franco JL, Brunda MJ, Wiltrout RH: Administration of Interleukin 12 with a pulse interleukin 2 and the rapid and complete eradication of murine renal cell carcinoma. J Natl Cancer Inst 88: 38-43, 1996.
13. Atzpodien J, Kirchner H Hanninen EL, Decken M, Fenner M, Poliwoda H: Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer. Eur J Cancer 29A suppl 5, P: S6-8, 1993.
14. Lopez Hänninen E, Kirchner H, Atzpodien J: Interleukin-2 based home thelapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J Urol 155: 19-25, 1996.
15. Hofinockel G, Theiß M, Gruß A, Langer W, Frohmüller H: Immunchemotherapie des metadasierten Nierenzellkarzinoms mit Interleukin-2, Interfeton-a und 5-Fluoromacil. Urologe A 36: 45-49, 1997.
16. Atzpodien J, Kircbner H, Franzke A, Wandelt T, Probst M, Buer J, Duensing S, Ganser A: Results of a randomized clinicsl trial comparing sc interleukin 2, sc alpha-2a-interferon, and iv bolus 5-fluorouracil agsinst oral tamoxifen in progressive metastatic renal cell carcinoma patients. Proc ASCO 16: A1164, 1997.
17. Atzpodien J, Kirchner H, Duensing S, Lopez-Hänninen E, Franzke A, Buer J, Probst M, Anton P, Poliwoda H: Biochemotherapy of advanced metastatic renal cell carcinoma: results of tbe combination of interlalkin 2, alpha-interferon, 5-fluoloulacil, vinblastine and 13-cis-retinoic acid. World J Urol 13, P: 174-177, 1995.
18. Atzpodien J, Buer J, Probst M, Duensing S, Kircbner H, Ganser A: Clinical snd pre-clinical role of 13-cis-reinoic acid in renal cell catcinoma: Hannover experience. Proc ASCO 15: A625, 1996.
19. Motzer RJ, Schwartz L, Law IM, Murphy BA, Hoffman AD, Albino AP, Vlamis V, Naous DM: Interfemn alfia-2a and 13-cis-retinoic acid in renal cell carcinoma: atditmnor activty in a phase II trial and interactions in vitro. J Clin Oncol 13, P: 1950-1957, 1995.
20. Escudier B, Ravaud A, Berton D, Chevreau C, Douillard JY, Dietrich PY: Phase II study of interfeton-a and all trsns-tetinoic acid in metastatic renal cell catcinoma Proc ASCO 15: A676, 1996.
21. Stadler WM, Tlabay K, Vogelzang NJ: Intedeukin-2 (IL2), interfeton-alpba (IFNA) and cis-retinoic acid (CRA): an effective outpatient regimen for metastatic renal cell carcinoma (RCC). Proc ASCO 15: A602, 1996.
22. Sawczuk I, Petrylak D, Benedetto P, Bertis R, Bukowski R, Dreicer R Einstein A, Ellerhorst J, Goodman G, Graham S, Harris D, Kempf R, Klarnet J, Kuzel T, Leong S, Logan T, Meyers F, Miller W, Murphy B, McCaffrey R, Walther P, Williams D, Hawkins M: Randomized controlled trial of ex vivo activated T-cells vs Interferon alpha in metastatic renal cancer. J Urol 159: A740, 1998.
23. Sawczuk I Armentrout S, Babayan R Graham S, Holden S, Klarnet J, Kuzel T, Leong S, Smith JA, White C: Adjuvant autolymphocyte therapy in the treatment of T1-3a,b,c or T4N0M0 renal cell carcinoma. J Urol 159: A653, 1998.
24. Rosenberg SA? Lotze MT, Yang JC: Prospective randomized trial of high-dose interleukin-2 alone or in comjunction with with lymphokme-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 85: 622-632, 1993.
25. Kleinknecht S, Bichler KEI, Strohmaier WL: Lnfluence of immunotherapy (IL2 + LAK + mhibition of prostaglandin synthesis) on peripheral blood parameters in patients with renal cell carcinoma. Urol Int 50: 121-128, 1993.
26. Pierce WC, Belldegruen A, Figlin RA: Cellular therapy: scientific rationale and climcal results in the treatment of metastatic renal-cell carcinoma. Sem Oncol 22: 74-80, 1995.
27. Hinkel A, Gitlitz BJ, Kaboo R, Mulders P, DeKernion JB, Figlin RA, Belldegruen A: Dendritic cell (DC) therapy fro metastatic renal cell cancer (mRCC): from baseline research to phase I clinical trial. J Urol 159: A564, 1998.
28. Tanguay S, Chagnon F, Bergeron F, Aprikian AG, Gervais F: Dendritic cell vaccine: a potential treatment for metastatic renal cell carcinoma. J Urol 159: A563, 1998.
29. Asano T, Khann A, Lagman M, Li B, Sutbanthiran M: Immunostimulatory therapy with anti-CD3 monoclonal antibodies and recombinant interleukin 2; heightened in vivo expression of mRNA encoding cytotoxic attack molecules and immunoregulatory cytokines and regression of mmine renal carcinoma. J Urol 157: 2396-2401, 1997.
30. Uemura H, Nakagawa Y, Okajima E, Hirao Y, Yoshikawa K, Saga S, Oosterwijk E: MN target immunotherapy for renal cell carcinoma. J Urol 159: A724, 1998.
31. Stadick H, Elsässer D, Valerius T, Schafllauser W: Praklinische Studien zum kombinierten Einsatz bispezifischer Antikörper und zytokinstimulierter Effektorzellen in der Imnmntherapie des Nierenzellkarzinoms. Anticancer Res, in press, 1999.
32. Steffens MG, Boerman OC, Oyen WJG, DeMulder PHM, Witjes JA, Oosterfof GON, Cortsens FHM, Debruyne FMJ, Oosterwijk E: Radioimmunotherapy with 131I-cG250 manoclonal antibody in patients with metastatic RCC, a phase IIII study. J Urol 159: A562, 1998.
33. Shirakawa T, Gardner TA, Kao C, Ko SC, Miyamoto T, Chun LWK, Bander NH, Woo S, Gotoh A, Kamidono S: Ablative gene therapy treatment of human renal cell carcinoma: cytosine deaminase plus 5-fluorocytosine has superior bystander effect over thymidine kinsse plus acyclovir. J Urol 159: A558, 1998.
34. Tachibana M, Sumitomo M, Asakura H, Murai M, Hayashi M, Takayanagi J, Shimizu N: Gene therapy by interleukin-1 receptor antagonist transfection in cytokine producing lurological cancer cells. J Urol 759: A756, 1998.
35. Onishi T, Imagawa K: Combined therapy of DANN methyl transferase inhibitor and interferon-a for renall cell carcinoma to change humoral to cellular immunity. J Urol 759: A734, 1998.
36. Seigne J, Turner J, Hackney J, Pow-Sang J, Helal M, Lockhatt J, Yu H: Gene therapy of renal cell carcinoma: a pilot study using the gene gun. J Urol 159: A573, 1998.
37. Thalmann GN, Cecchini MG, Gautschi E, Wetterwald A, Miescher S, Studer UE, Stadler BM: Targeting genes to the vasculature of human renal cell carcinoma (RCC) using mimotopes. J Urol 159: A556, 1998.
38. Takabashi A, Sasamura H, Mivao N, Yanase M, Masumori N, Oda T, Itoh N, Honta H Tsukamoto T: Inhibition of angiogenesis for treatment of renal cell carcinoma. J Urol 759: A643, 1998.
39. Finkenzeller G Manne D: Angiogeneseinhlbition. Pretentation at Nierenzellkarzinom-Tübingen Symposium, 1998.
40. Killion JJ, Nelkin G, Slaton JW: Incorporation; of interleukin-2 into liposomes containing maaopbage activators as therapy for lung metastases of murine renal cell carcinoma (RENCA). J Urol 159: A569, 1998.
41. Hofer C, Gobel R, Deering P, Zawatzky R, Cevc G, Breul J: Produktion Interleulcin-2 und Interferon-alpha tragender Transfersome (TF) zur transdennalen Immlmtherapie des metastasierten Nierenzellkalzinoms. Anticancer Res, in press, 1999.
42. Hu SI, Jonsson J, Gotley D, Thompson L, Nicol D: Captopril inhibits human lenal cell carcinoma in a xenograft model. J Urol 159: A759, 1998.
43. Kleinknecht S, Bichler KH, Strohmaier WI: Intercellular adhesion molecule 1 (ICAM-1) and insulinlike growth factor 1 (IGF-1) in patients with renal cell carcinoma. Abstr Symp Exp Urol Wuppertal 1992.
44. Höbarth K Hallas A, Steiner G, Gomahr A, Aulitzky W, Marberger M: Circulating immune markers in advanced renal cell carcinoma during immunotherapy with interferon gamma. Urol Res 24: 101-106, 1996.
45. Bain C, Merrouche Y, Puisieux I, Blay JY, Negrier S, Bonadona V, Lasset C, Lanier F, Duc A, Gebuhrer L, Philip T, Favrot MC Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carcinoma. Br J Cancer 75: 283-286, 1996.
46. Wetterauer U, Schultze-Seemann W, Elsäßer-Beile U: Korrelation von klinischen und immunologischen Parametem bei Patienten mit Nierenzellkalzinomen unter Therapie mit Zytokinen und Isoretinoin. Anticancer Res, in press, 1999.
47. Georg C, Fischer C, Terpe HJ, Schulz A, Stolkel S, Weidner W: Kljnische Daten zur prognostischen Bedeutung von Zelladhäsionsmolekülen beim Nierenzellkarzinom an n=137 Fällen. Anticancer Res, in press, 1999.
48. Gohnng B, Riemann D, Rebmann U, Heynemann H, Schabel J, Langner J: Prognostic value of the immunomonitoring of patients with renal cell carcinoma under therapy with IL-2/IFN-a-2 in combination with 5-FU. Urol Res 24: 297-303, 1996.
49. Duensing S, Vandenbergderuiter E, Störkel S, Kirchner H, Hänninen EL, Buer J, Poliwoda H, Atzpodien J: Cytogenetic studies in renal cell carcinoma patients receiving low-dose recombinant mterleukin 2 based immunotherapy. Tumor Biol 17: 27-33, 1996.
50. Schafhauser W, Liedl T, Elsässer D, T. Zörcher, Schrott K: Flow cytometric analysis of DNA-aneuploidy subgroups and proliferation in renal cell carcinoma. Anticancer Res 19: 1471-1476, 19999.
51. Schmidt DS, Händel D, Corvin S, Basting RF: DNA-Analyse gestiitzte Prognoseabschötzung beim Nierenzellkarzinom. Anticancer Res, in press, 1999.
52. Levy DA, Swanson DA, Slaton JW, Ellerhorst J, Dinney CP: Timely delivery of biological therapy after cytoreductive nephrectomy in carefully sekected patients with metastatic renal cell carcinoma. J Urol 159: 1168-1173, 1998.
53. Bennet RT, Lerner SE, Taub HC, Dutcher n Fleischmann J: Cytoreductive surgery for stage IV renal cell carcinoma. J Urol 154: 32-34, 1995.
54. Fallick ML, McDermott DF, LaRock D, Long JP, Atkins MB: Nephrectomy before interleulcin-2 therapy for patients with metastatic renal cell carcinoma. J Urol 158: 1691-1695, 1997.
55. Novick AC: Cu reid surgical approaches, nephron-sparing surgery, and the role of surgery in the integrated immunological approachto renal cell carcinoma. Sem Oncol 22: 29-33, 1995.
56. Walther MM, Yang JC, Pass HI, Linehan WM, Rosenberg SA: Cytoreductive surgery before hlgh does interleukin-2 based therapy in patients with metastatic renal cell carcinoma. J Urol 158: 1675-1678, 1997.
57. Ljungberg B, Hemiksson R: Imnunotherapy of metastatic renal cell carcinoma. Curr Op Urol 7: 252-258, 1997.